UBT SRL (Umbria Bioengineering Technologies), born as academic Spin Off of the Department of Physics and Geology of the University of Perugia, Italy, is a biomedical company which develops and commercialises a portfolio of innovative medical imaging devices based on cutting-edge microwaves technology instead of dangereous ionizing radiation (X-Rays).
UBT's microwave imaging technology achieves the accuracy of X-Rays without the risks and limitations associated with ionizing radiations. The innovative imaging technology employs low power microwaves – non-ionizing electromagnetic radiations, such as those commonly used in mobile communications.
UBT has so far developed two different products (patented):
- MammoWave. MammoWave is a novel X-Rays free mammogram for breast cancer screening.
- BrainWave. BrainWave is a novel device for brain stroke detection and classification.
MammoWave has been recently awarded with a EU H2020 SME Instrument Phase 2 grant. MammoWave use for clinical trials was authorized by Italian Ministry of Health and by the Ethical Committee of Regione Umbria, Italy. Clinical trials are ongoing at Perugia Hospital, S. Maria della Misericordia, and at Foligno Hospital. Thanks to the SME Instrument Phase 2 funding, UBT is now enrolling patients in further four Hospitals, including Humanitas, Milano and San Martino, Genova, in Italy; Universitätsklinikum Erlangen in Germany; Hospital Virgen de la Salud in Toledo, in Spain.
In September 2019, UBT SRL became a full member of the Innovation Centre at London Southbank University, London, establishing a UK subsidiary (UBT UK DIVISION LIMITED, no: 13096679) focused on research activities related to Artificial Intelligence and to the extension of microwave imaging to other diagnostic applications.
UBT SRL is ISO 13485 certified.